- Home
- GLPG vs BLBD Comparison
GLPG vs BLBD Comparison
Compare GLPG & BLBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- BLBD
- Stock Information
- Founded
- GLPG 1999
- BLBD 1927
- Country
- GLPG Belgium
- BLBD United States
- Employees
- GLPG N/A
- BLBD N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- BLBD Construction/Ag Equipment/Trucks
- Sector
- GLPG Health Care
- BLBD Consumer Discretionary
- Exchange
- GLPG Nasdaq
- BLBD Nasdaq
- Market Cap
- GLPG 2.1B
- BLBD 1.7B
- IPO Year
- GLPG 2005
- BLBD N/A
- Fundamental
- Price
- GLPG $31.78
- BLBD $49.96
- Analyst Decision
- GLPG Hold
- BLBD Strong Buy
- Analyst Count
- GLPG 4
- BLBD 6
- Target Price
- GLPG $30.00
- BLBD $58.67
- AVG Volume (30 Days)
- GLPG 229.6K
- BLBD 437.6K
- Earning Date
- GLPG 11-05-2025
- BLBD 11-24-2025
- Dividend Yield
- GLPG N/A
- BLBD N/A
- EPS Growth
- GLPG N/A
- BLBD 15.49
- EPS
- GLPG N/A
- BLBD 3.49
- Revenue
- GLPG $323,674,692.00
- BLBD $1,420,946,000.00
- Revenue This Year
- GLPG $1.77
- BLBD $9.94
- Revenue Next Year
- GLPG $0.44
- BLBD $4.25
- P/E Ratio
- GLPG N/A
- BLBD $14.32
- Revenue Growth
- GLPG 5.43
- BLBD 9.31
- 52 Week Low
- GLPG $22.36
- BLBD $30.04
- 52 Week High
- GLPG $37.78
- BLBD $61.95
- Technical
- Relative Strength Index (RSI)
- GLPG 43.66
- BLBD 32.94
- Support Level
- GLPG $30.92
- BLBD $49.48
- Resistance Level
- GLPG $32.62
- BLBD $54.18
- Average True Range (ATR)
- GLPG 0.84
- BLBD 2.02
- MACD
- GLPG -0.26
- BLBD -0.58
- Stochastic Oscillator
- GLPG 21.08
- BLBD 5.32
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About BLBD Blue Bird Corporation
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.